|
1
|
Lusis AJ: Atherosclerosis. Nature.
407:233–241. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karagiannis GS, Weile J, Bader GD and
Minta J: Integrative pathway dissection of molecular mechanisms of
moxLDL-induced vascular smooth muscle phenotype transformation. BMC
Cardiovasc Disord. 13:42013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Doran AC, Meller N and McNamara CA: Role
of smooth muscle cells in the initiation and early progression of
atherosclerosis. Arterioscler Thromb Vasc Biol. 28:812–819. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hao H, Gabbiani G and Bochaton-Piallat ML:
Arterial smooth muscle cell heterogeneity: Implications for
atherosclerosis and restenosis development. Arterioscler Thromb
Vasc Biol. 23:1510–1520. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim K, Mayer EP and Nachtigal M:
Galectin-3 expression in macrophages is signaled by Ras/MAP kinase
pathway and up-regulated by modified lipoproteins. Biochim Biophys
Acta. 1641:13–23. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Markowska AI, Liu FT and Panjwani N:
Galectin-3 is an important mediator of VEGF- and bFGF-mediated
angiogenic response. J Exp Med. 207:1981–1993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calvier L, Miana M, Reboul P, Cachofeiro
V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad
F, Rossignol P and López-Andrés N: Galectin-3 mediates
aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc
Biol. 33:67–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dumic J, Dabelic S and Flögel M:
Galectin-3: An open-ended story. Biochim Biophys Acta.
1760:616–635. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shimura T, Takenaka Y, Tsutsumi S, Hogan
V, Kikuchi A and Raz A: Galectin-3, a novel binding partner of
beta-catenin. Cancer Res. 64:6363–6367. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimura T, Takenaka Y, Fukumori T,
Tsutsumi S, Okada K, Hogan V, Kikuchi A, Kuwano H and Raz A:
Implication of galectin-3 in Wnt signaling. Cancer Res.
65:3535–3537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song S, Mazurek N, Liu C, Sun Y, Ding QQ,
Liu K, Hung MC and Bresalier RS: Galectin-3 mediates nuclear
beta-catenin accumulation and Wnt signaling in human colon cancer
cells by regulation of glycogen synthase kinase-3beta activity.
Cancer Res. 69:1343–1349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Francia P, Adduci C, Semprini L, Borro M,
Ricotta A, Sensini I, Santini D, Caprinozzi M, Balla C, Simmaco M
and Volpe M: Osteopontin and galectin-3 predict the risk of
ventricular tachycardia and fibrillation in heart failure patients
with implantable defibrillators. J Cardiovasc Electrophysiol.
25:609–616. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
de Boer RA, Edelmann F, Cohen-Solal A,
Mamas MA, Maisel A and Pieske B: Galectin-3 in heart failure with
preserved ejection fraction. Eur J Heart Fail. 15:1095–1101. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Felker GM, Fiuzat M, Shaw LK, Clare R,
Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad
F, et al: Galectin-3 in ambulatory patients with heart failure:
Results from the HF-ACTION study. Circ Heart Fail. 5:72–78. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mayr A, Klug G, Mair J, Streil K,
Harrasser B, Feistritzer HJ, Jaschke W, Schocke M, Pachinger O and
Metzler B: Galectin-3: Relation to infarct scar and left
ventricular function after myocardial infarction. Int J Cardiol.
163:335–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sanchez-Mas J, Lax A, Asensio-Lopez MC,
Fernandez-Del Palacio MJ, Caballero L, Garrido IP, Pastor F,
Januzzi JL and Pascual-Figal DA: Galectin-3 expression in cardiac
remodeling after myocardial infarction. Int J Cardiol.
172:e98–e101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van Kimmenade RR, Januzzi JL Jr, Ellinor
PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA,
Menheere PP and Pinto YM: Utility of amino-terminal pro-brain
natriuretic peptide, galectin-3, and apelin for the evaluation of
patients with acute heart failure. J Am Coll Cardiol. 48:1217–1224.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szadkowska I, Wlazel RN, Migala M,
Bajon-Laskowska K, Szadkowski K, Zielińska M, Paradowski M and
Pawlicki L: The association between galectin-3 and occurrence of
reinfarction early after first myocardial infarction treated
invasively. Biomarkers. 18:655–659. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nachtigal M, Ghaffar A and Mayer EP:
Galectin-3 gene inactivation reduces atherosclerotic lesions and
adventitial inflammation in ApoE-deficient mice. Am J Pathol.
172:247–255. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seferovic JP, Lalic NM, Floridi F, Tesic
M, Seferovic PM, Giga V, Lalic K, Jotic A, Jovicic S, Colak E, et
al: Structural myocardial alterations in diabetes and hypertension:
The role of galectin-3. Clin Chem Lab Med. 52:1499–1505.
2014.PubMed/NCBI
|
|
21
|
Yilmaz H, Cakmak M, Inan O, Darcin T and
Akcay A: Increased levels of galectin-3 were associated with
prediabetes and diabetes: New risk factor? J Endocrinol Invest.
38:527–533. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guyton JR, Lenz ML, Mathews B, Hughes H,
Karsan D, Selinger E and Smith CV: Toxicity of oxidized low density
lipoproteins for vascular smooth muscle cells and partial
protection by antioxidants. Atherosclerosis. 118:237–249. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leavesley DI, Schwartz MA, Rosenfeld M and
Cheresh DA: Integrin beta 1- and beta 3-mediated endothelial cell
migration is triggered through distinct signaling mechanisms. J
Cell Biol. 121:163–170. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tickenbrock L, Schwäble J, Strey A, Sargin
B, Hehn S, Baas M, Choudhary C, Gerke V, Berdel WE, Müller-Tidow C
and Serve H: Wnt signaling regulates transendothelial migration of
monocytes. J Leukoc Biol. 79:1306–1313. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schaale K, Neumann J, Schneider D, Ehlers
S and Reiling N: Wnt signaling in macrophages: Augmenting and
inhibiting mycobacteria-induced inflammatory responses. Eur J Cell
Biol. 90:553–559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nangia-Makker P, Honjo Y, Sarvis R,
Akahani S, Hogan V, Pienta KJ and Raz A: Galectin-3 induces
endothelial cell morphogenesis and angiogenesis. Am J Pathol.
156:899–909. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jia W, Kidoya H, Yamakawa D, Naito H and
Takakura N: Galectin-3 accelerates M2 macrophage infiltration and
angiogenesis in tumors. Am J Pathol. 182:1821–1831. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carthy JM, Luo Z and McManus BM: WNT3A
induces a contractile and secretory phenotype in cultured vascular
smooth muscle cells that is associated with increased gap junction
communication. Lab Invest. 92:246–255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rensen SS, Doevendans PA and van Eys GJ:
Regulation and characteristics of vascular smooth muscle cell
phenotypic diversity. Neth Heart J. 15:100–108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matsushita T, Rama A, Charolidi N, Dupont
E and Severs NJ: Relationship of connexin43 expression to
phenotypic modulation in cultured human aortic smooth muscle cells.
Eur J Cell Biol. 86:617–628. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rama A, Matsushita T, Charolidi N, Rothery
S, Dupont E and Severs NJ: Up-regulation of connexin43 correlates
with increased synthetic activity and enhanced contractile
differentiation in TGF-beta-treated human aortic smooth muscle
cells. Eur J Cell Biol. 85:375–386. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Menini S, Iacobini C, Ricci C, Fantauzzi C
Blasetti, Salvi L, Pesce CM, Relucenti M, Familiari G, Taurino M
and Pugliese G: The galectin-3/RAGE dyad modulates vascular
osteogenesis in atherosclerosis. Cardiovasc Res. 100:472–480. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kobayashi T, Shimura T, Yajima T, Kubo N,
Araki K, Tsutsumi S, Suzuki H, Kuwano H and Raz A: Transient gene
silencing of galectin-3 suppresses pancreatic cancer cell migration
and invasion through degradation of β-catenin. Int J Cancer.
129:2775–2786. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang D, Chen ZG, Liu SH, Dong ZQ, Dalin
M, Bao SS, Hu YW and Wei FC: Galectin-3 gene silencing inhibits
migration and invasion of human tongue cancer cells in vitro via
downregulating β-catenin. Acta Pharmacol Sin. 34:176–184. 2013.
View Article : Google Scholar : PubMed/NCBI
|
